Evaluation of [ 64Cu]Cu-DOTA and [ 64Cu]Cu-CB-TE2A chelates for targeted positron emission tomography with an α vβ 6-Specific peptide

Julie Sutcliffe, Sven H. Hausner, David L. Kukis, M. Karen J Gagnon, Catherine E. Stanecki, Riccardo Ferdani, John F. Marshall, Carolyn J. Anderson

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Significant upregulation of the integrin α vβ 6 has been described as a prognostic indicator in several cancers, making it an attractive target for tumor imaging. This study compares variants of a PEGylated α vβ 6-targeting peptide, bearing either an [ 18F]fluorobenzoyl prosthetic group ([ 18F]FBA- PEG-A20FMDV2) or different [ 64Cu]copper chelators (DOTA-PEG- A20FMDV2, CB-TE2A-PEG-A20FMDV2). The compounds were evaluated in vitro by enzyme-linked immunosorbent assay (against the integrin α vβ 6 and the closely related integrin α vβ 3) and by cell labeling (α v6-positive DX3puroP6/α vβ 6-negative DX3puro) and in vivo using micro-positron emission tomography in a mouse model bearing paired DX3puroP6/Dx3puro xenografts. In vitro, all three compounds showed excellent α vβ 6-specific binding (50% inhibitory concentration [IC 50](α vβ 6) = 3 to 6 nmol/L; IC 50vβ 3) > 10 Hmol/L). In vivo, they displayed comparable, preferential uptake for the α vβ 6-expressing xenograft over the α vβ 6-negative control (> 4:1 ratio at 4 hours postinjection). Whereas [ 64Cu]Cu-DOTA-PEG-A20FMDV2 resulted in increased levels of radioactivity in the liver, [ 64Cu]Cu-CB-TE2A-PEG-A20FMDV2 did not. Significantly, both 64Cu-labeled tracers showed unexpectedly high and persistent levels of radioactivity in the kidneys (> 40% injected dose/g at 4 and 12 hours postinjection). The findings underscore the potential influence of the prosthetic group on targeted in vivo imaging of clinically relevant markers such as <α vβ 6. Despite identical targeting peptide moiety and largely equal in vitro behavior, both 64Cu-labeled tracers displayed inferior pharmacokinetics, making them in their present form less suitable candidates than the 18F-labeled tracer for in vivo imaging of α vβ 3.

Original languageEnglish (US)
Pages (from-to)111-121
Number of pages11
JournalMolecular Imaging
Volume8
Issue number2
DOIs
StatePublished - Mar 2009

Fingerprint

Positron emission tomography
chelates
Integrins
Positron-Emission Tomography
Peptides
Polyethylene glycols
peptides
tracers
positrons
tomography
radioactivity
Heterografts
Bearings (structural)
Radioactivity
evaluation
Prosthetics
Imaging techniques
kidneys
Chelating Agents
liver

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Biotechnology
  • Molecular Medicine
  • Biomedical Engineering
  • Condensed Matter Physics

Cite this

Evaluation of [ 64Cu]Cu-DOTA and [ 64Cu]Cu-CB-TE2A chelates for targeted positron emission tomography with an α vβ 6-Specific peptide. / Sutcliffe, Julie; Hausner, Sven H.; Kukis, David L.; Karen J Gagnon, M.; Stanecki, Catherine E.; Ferdani, Riccardo; Marshall, John F.; Anderson, Carolyn J.

In: Molecular Imaging, Vol. 8, No. 2, 03.2009, p. 111-121.

Research output: Contribution to journalArticle

Sutcliffe, J, Hausner, SH, Kukis, DL, Karen J Gagnon, M, Stanecki, CE, Ferdani, R, Marshall, JF & Anderson, CJ 2009, 'Evaluation of [ 64Cu]Cu-DOTA and [ 64Cu]Cu-CB-TE2A chelates for targeted positron emission tomography with an α vβ 6-Specific peptide', Molecular Imaging, vol. 8, no. 2, pp. 111-121. https://doi.org/10.2310/7290.2009.00015
Sutcliffe, Julie ; Hausner, Sven H. ; Kukis, David L. ; Karen J Gagnon, M. ; Stanecki, Catherine E. ; Ferdani, Riccardo ; Marshall, John F. ; Anderson, Carolyn J. / Evaluation of [ 64Cu]Cu-DOTA and [ 64Cu]Cu-CB-TE2A chelates for targeted positron emission tomography with an α vβ 6-Specific peptide. In: Molecular Imaging. 2009 ; Vol. 8, No. 2. pp. 111-121.
@article{6f32834f9147417db81ad324255f1705,
title = "Evaluation of [ 64Cu]Cu-DOTA and [ 64Cu]Cu-CB-TE2A chelates for targeted positron emission tomography with an α vβ 6-Specific peptide",
abstract = "Significant upregulation of the integrin α vβ 6 has been described as a prognostic indicator in several cancers, making it an attractive target for tumor imaging. This study compares variants of a PEGylated α vβ 6-targeting peptide, bearing either an [ 18F]fluorobenzoyl prosthetic group ([ 18F]FBA- PEG-A20FMDV2) or different [ 64Cu]copper chelators (DOTA-PEG- A20FMDV2, CB-TE2A-PEG-A20FMDV2). The compounds were evaluated in vitro by enzyme-linked immunosorbent assay (against the integrin α vβ 6 and the closely related integrin α vβ 3) and by cell labeling (α v,β 6-positive DX3puroP6/α vβ 6-negative DX3puro) and in vivo using micro-positron emission tomography in a mouse model bearing paired DX3puroP6/Dx3puro xenografts. In vitro, all three compounds showed excellent α vβ 6-specific binding (50{\%} inhibitory concentration [IC 50](α vβ 6) = 3 to 6 nmol/L; IC 50(α vβ 3) > 10 Hmol/L). In vivo, they displayed comparable, preferential uptake for the α vβ 6-expressing xenograft over the α vβ 6-negative control (> 4:1 ratio at 4 hours postinjection). Whereas [ 64Cu]Cu-DOTA-PEG-A20FMDV2 resulted in increased levels of radioactivity in the liver, [ 64Cu]Cu-CB-TE2A-PEG-A20FMDV2 did not. Significantly, both 64Cu-labeled tracers showed unexpectedly high and persistent levels of radioactivity in the kidneys (> 40{\%} injected dose/g at 4 and 12 hours postinjection). The findings underscore the potential influence of the prosthetic group on targeted in vivo imaging of clinically relevant markers such as <α vβ 6. Despite identical targeting peptide moiety and largely equal in vitro behavior, both 64Cu-labeled tracers displayed inferior pharmacokinetics, making them in their present form less suitable candidates than the 18F-labeled tracer for in vivo imaging of α vβ 3.",
author = "Julie Sutcliffe and Hausner, {Sven H.} and Kukis, {David L.} and {Karen J Gagnon}, M. and Stanecki, {Catherine E.} and Riccardo Ferdani and Marshall, {John F.} and Anderson, {Carolyn J.}",
year = "2009",
month = "3",
doi = "10.2310/7290.2009.00015",
language = "English (US)",
volume = "8",
pages = "111--121",
journal = "Molecular Imaging",
issn = "1535-3508",
publisher = "Decker Publishing",
number = "2",

}

TY - JOUR

T1 - Evaluation of [ 64Cu]Cu-DOTA and [ 64Cu]Cu-CB-TE2A chelates for targeted positron emission tomography with an α vβ 6-Specific peptide

AU - Sutcliffe, Julie

AU - Hausner, Sven H.

AU - Kukis, David L.

AU - Karen J Gagnon, M.

AU - Stanecki, Catherine E.

AU - Ferdani, Riccardo

AU - Marshall, John F.

AU - Anderson, Carolyn J.

PY - 2009/3

Y1 - 2009/3

N2 - Significant upregulation of the integrin α vβ 6 has been described as a prognostic indicator in several cancers, making it an attractive target for tumor imaging. This study compares variants of a PEGylated α vβ 6-targeting peptide, bearing either an [ 18F]fluorobenzoyl prosthetic group ([ 18F]FBA- PEG-A20FMDV2) or different [ 64Cu]copper chelators (DOTA-PEG- A20FMDV2, CB-TE2A-PEG-A20FMDV2). The compounds were evaluated in vitro by enzyme-linked immunosorbent assay (against the integrin α vβ 6 and the closely related integrin α vβ 3) and by cell labeling (α v,β 6-positive DX3puroP6/α vβ 6-negative DX3puro) and in vivo using micro-positron emission tomography in a mouse model bearing paired DX3puroP6/Dx3puro xenografts. In vitro, all three compounds showed excellent α vβ 6-specific binding (50% inhibitory concentration [IC 50](α vβ 6) = 3 to 6 nmol/L; IC 50(α vβ 3) > 10 Hmol/L). In vivo, they displayed comparable, preferential uptake for the α vβ 6-expressing xenograft over the α vβ 6-negative control (> 4:1 ratio at 4 hours postinjection). Whereas [ 64Cu]Cu-DOTA-PEG-A20FMDV2 resulted in increased levels of radioactivity in the liver, [ 64Cu]Cu-CB-TE2A-PEG-A20FMDV2 did not. Significantly, both 64Cu-labeled tracers showed unexpectedly high and persistent levels of radioactivity in the kidneys (> 40% injected dose/g at 4 and 12 hours postinjection). The findings underscore the potential influence of the prosthetic group on targeted in vivo imaging of clinically relevant markers such as <α vβ 6. Despite identical targeting peptide moiety and largely equal in vitro behavior, both 64Cu-labeled tracers displayed inferior pharmacokinetics, making them in their present form less suitable candidates than the 18F-labeled tracer for in vivo imaging of α vβ 3.

AB - Significant upregulation of the integrin α vβ 6 has been described as a prognostic indicator in several cancers, making it an attractive target for tumor imaging. This study compares variants of a PEGylated α vβ 6-targeting peptide, bearing either an [ 18F]fluorobenzoyl prosthetic group ([ 18F]FBA- PEG-A20FMDV2) or different [ 64Cu]copper chelators (DOTA-PEG- A20FMDV2, CB-TE2A-PEG-A20FMDV2). The compounds were evaluated in vitro by enzyme-linked immunosorbent assay (against the integrin α vβ 6 and the closely related integrin α vβ 3) and by cell labeling (α v,β 6-positive DX3puroP6/α vβ 6-negative DX3puro) and in vivo using micro-positron emission tomography in a mouse model bearing paired DX3puroP6/Dx3puro xenografts. In vitro, all three compounds showed excellent α vβ 6-specific binding (50% inhibitory concentration [IC 50](α vβ 6) = 3 to 6 nmol/L; IC 50(α vβ 3) > 10 Hmol/L). In vivo, they displayed comparable, preferential uptake for the α vβ 6-expressing xenograft over the α vβ 6-negative control (> 4:1 ratio at 4 hours postinjection). Whereas [ 64Cu]Cu-DOTA-PEG-A20FMDV2 resulted in increased levels of radioactivity in the liver, [ 64Cu]Cu-CB-TE2A-PEG-A20FMDV2 did not. Significantly, both 64Cu-labeled tracers showed unexpectedly high and persistent levels of radioactivity in the kidneys (> 40% injected dose/g at 4 and 12 hours postinjection). The findings underscore the potential influence of the prosthetic group on targeted in vivo imaging of clinically relevant markers such as <α vβ 6. Despite identical targeting peptide moiety and largely equal in vitro behavior, both 64Cu-labeled tracers displayed inferior pharmacokinetics, making them in their present form less suitable candidates than the 18F-labeled tracer for in vivo imaging of α vβ 3.

UR - http://www.scopus.com/inward/record.url?scp=67649312034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649312034&partnerID=8YFLogxK

U2 - 10.2310/7290.2009.00015

DO - 10.2310/7290.2009.00015

M3 - Article

C2 - 19397856

AN - SCOPUS:67649312034

VL - 8

SP - 111

EP - 121

JO - Molecular Imaging

JF - Molecular Imaging

SN - 1535-3508

IS - 2

ER -